Considering the risks of cardiovascular events associated with the use of COX-2 inhibitors, together with the increasing appreciation that the net effects of COX-2 inhibition depend on the type of cells involved [6], [16], determining the role of distinct cell sources of COX-2 in the progression of tissue damage may provide important insights into the mechanisms of liver IRI. Here, PTGS2 is linked to digestive system neoplasm.